Drug Profile
Research programme: antiretrovirals - Mutabilis
Latest Information Update: 29 Aug 2023
Price :
$50
*
At a glance
- Originator Mutabilis
- Class Small molecules
- Mechanism of Action Human immunodeficiency virus protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 29 Aug 2023 Discontinued - Preclinical for HIV infections in France (unspecified route)
- 28 Feb 2020 No recent reports of development identified for preclinical development in HIV-infections in France
- 25 Jan 2016 Preclinical trials in HIV infections in France (unspecified route) before January 2016